Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Cannabidiol  COVID-19 treatment studies for Cannabidiol  C19 studies: Cannabidiol  Cannabidiol   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 50% Improvement Relative Risk Case (b) 33% c19early.org/cbd Nguyen et al. Cannabidiol for COVID-19 Prophylaxis Favors cannabidiol Favors control
Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses
Nguyen et al., Science Advances, doi:10.1126/sciadv.abi6110 (date from earlier preprint)
Nguyen et al., Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune.., Science Advances, doi:10.1126/sciadv.abi6110 (date from earlier preprint)
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,212 patients in the USA with a history of seizure-related conditions, showing patients treated with CBD100 had significantly lower incidence of COVID-19 cases compared to a matched control group.
In Vitro study showing CBD inhibits SARS-CoV-2 with Vero E6 and Calu-3 cells. Mouse study showing CBD significantly inhibited viral replication in the lung and nasal turbinate.
Authors note that CBD does not inhibit ACE2 expression or the main viral proteases, inhibition occurs after viral entry. Authors stress several limitations for use at this time, including purity, quality, and the formulation of products, and potential lung damage based on administration method.
Authors recommend clinical trials, but do not mention the existing RCT by Crippa et al.
risk of case, 49.6% lower, RR 0.50, p = 0.006, treatment 26 of 531 (4.9%), control 48 of 531 (9.0%), NNT 24, odds ratio converted to relative risk, active CBD100 users.
risk of case, 32.9% lower, RR 0.67, p = 0.009, treatment 75 of 1,212 (6.2%), control 108 of 1,212 (8.9%), NNT 37, odds ratio converted to relative risk, all CBD100 users.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Nguyen et al., 20 Jan 2022, retrospective, USA, peer-reviewed, 34 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Abstract: SCIENCE ADVANCES | RESEARCH ARTICLE CORONAVIRUS Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses Long Chi Nguyen1§, Dongbo Yang1§, Vlad Nicolaescu2,10§, Thomas J. Best3§, Haley Gula2,10, Divyasha Saxena4, Jon D. Gabbard4, Shao-Nong Chen5, Takashi Ohtsuki5†, John Brent Friesen5, Nir Drayman6, Adil Mohamed6, Christopher Dann1, Diane Silva7, Lydia Robinson-Mailman1, Andrea Valdespino1, Letícia Stock1, Eva Suárez1, Krysten A. Jones8, Saara-Anne Azizi8, Jennifer K. Demarco4, William E. Severson4, Charles D. Anderson4, James Michael Millis9, Bryan C. Dickinson8, Savaş Tay6, Scott A. Oakes7, Guido F. Pauli5, Kenneth E. Palmer4, The National COVID Cohort Collaborative Consortium‡, David O. Meltzer3, Glenn Randall2,10*, Marsha Rich Rosner1* Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). The spread of SARS-CoV-2 and ongoing COVID-19 pandemic underscores the need for new treatments. Here we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1 RNase endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against use of non-medical formulations including edibles, inhalants or topicals as a preventative or treatment therapy at the present time.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit